Loading...
•
Jun 30, 2021
Ashland Q3 2021 Earnings Report
Ashland's financial results for Q3 2021 were announced.
Key Takeaways
Ashland reported sales of $637 million, up 11% year-over-year, with net income of $80 million. Strong demand was partially offset by weakness in hand-sanitizer ingredients and Avoca. Global supply-chain and logistics disruptions also limited the company’s ability to meet all customer demand.
Sales reached $637 million, an 11% increase from the prior-year quarter.
Net income was $80 million, translating to $1.29 per diluted share.
Income from continuing operations was $87 million, or $1.40 per diluted share.
Cash flows from operating activities totaled $233 million, with free cash flows reaching $210 million.
Ashland
Ashland
Ashland Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comPersonal Care Revenue
CapyFin.comSpecialty Additives Revenue
CapyFin.comIntermediates Revenue
CapyFin.com Forward Guidance
Ashland's expectations for full-year results have not changed.
Revenue & Expenses
Visualization of income flow from segment revenue to net income